All Stories

  1. Interleukin-1β provided by KIT-competent mast cells is required for KRAS-mutant lung adenocarcinoma

    Article • OncoImmunology, April 2019, Taylor & Francis

    Professor Torsten Goldmann, Ioannis Lilis